PTO 14 JUN 2006

PORM PTO-1390 (REV 07-2005) 4439-4044 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 TBA INTERNATIONAL APPLICATION INTERNATIONAL FILING DATE EARLIEST PRIORITY DATE CLAIMED PCT/JP2004/018646 14 December 2004 15 December 2003 TITLE OF INVENTION AK ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE APPLICANT(S) FOR DO/EO/US 777 Masayuki NOGUCHI, Futoshi OKADA, and Shin HIROMURA Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.  $\Box$ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected. (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a.  $\square$  is attached hereto (required only if not communicated by the International Bureau). b. A has been communicated by the International Bureau. c. [] is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International application as filed (35 U.S.C. 371(c)(2)). a. ⊠ is attached hereto (Specification: 37 pgs., Claims: 3 pgs.; Abstract: 1 pg.; and 5 Sheets of Formal Drawings (Figs. 1-13)). □ has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Forms PTO-1449A and PTO-1449B, with copies of 13 cited references. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821-1.825 with the paper copy of the sequence listings: 4 pgs. and Sequence Listing Statement. 18. A second copy of the published international application under 35 U.S.C. 154(d)(4).

Copies of: PCT Request document; Forms: PCT/ISA/202; PCT/ISA/206; PCT/ISA/210; PCT/ISA/220; PCT/ISA/237; PCT/IB/301;

19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

PCT/IB/304, PCT/IB/307; PCT/IB/308; PCT/IB311 and PCT/IB/345 published PCT application >

Other items or Information:

# IAP20 Rec'd PCT/PTO 14 JUN 2006

U.S. APPLICATION NO. GF	DZNEQ	INTERNATIONAL APPLI	ICATION NO.		ATTORNEY'S DOCKET NO		
U.S. APPLICATION NO. GILLANDE TO SEE		4439-4044					
TOTAL				CALCULATIONS	PTO USE ONLY		
The following fees have been submitted 21.   Basic national fee					\$ 300		
	22. Examination fee  If the written opinion prepared by ISA/US or the international preliminary examination						
report prep	ared by IPEA/US indic	ates all claims satisfy pro	visions of				
PCT Article 33 (1)-(4)					\$ 200		
All other situations \$200					<u> </u>		
If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of							
PCT Articl	e 33(1) - (4)			\$0			
Search fee	(37 CFR 1.445(a)(2)) I	nas been paid on the inten	national application	to the			
Internation	al Search Report prepa	ning Authority red by an ISA other than	the US and provided	to the			
Office or previously communicated to the US by the IB\$400 All other situations					\$ 400		
All other si	TOTAL OF 2				\$ 900		
Additional fee fo	or specification and dra	wings filed in paper over	100 sheets (excluding	ng sequence			
listing or compu	ter program listing file eets of paper or fraction	d in an electronic medium thereof.	n). The fee is \$250 fo	r each			
		Number of each addition					
Total Sheets	Extra Sheets	thereof (round up to a w	hole number)	RATE	· · · · · · · · · · · · · · · · · · ·	-	
- 100 =	/50 =	oath or declaration lat	or than 20 months	x \$250.00	\$ <u> </u>		
earliest claimed price	ority date (37 CFR 1	.492(h)).	or trian 50 months	nom me	\$		
· · · · · ·	<u> </u>	NUMBER EXTRA	RATE		\$		
CLAIMS	NUMBER FILED				\$ 950		
Total claims	39 - 20 =		x \$50.0		\$ 400		
Independent claims	5 - 3 =		x \$200.		\$ 360		
MULTIPLE DEPENI	DENT CLAIM(S) (if a		+ \$360.				
Applicant claims	s small entity status. Se	te 37 CFR 1.27. The fees	BOVE CALCUL.		\$ 2,610		
/2							
	·	· <del>-</del> ·		TOTAL =	\$ 2,610	·	
Processing fee of \$136 claimed priority date		English translation later t	han 30 months from	the earliest			
ciamica priority date	(37 (31 (1.1)2(1)).	7	TOTAL NATION	AL FEE =	\$ 2,610		
		7 CFR 1.21(h)). The assi	gnment must be acco	ompanied by			
an appropriate cover s	sheet (37 CFR 3.28, 3.3	1). \$40.00 per property		+			
			OTAL FEES ENG	CLOSED =	Amount to be	<u> </u>	
					refunded:	\$	
					Amount to be	6	
	.1	4	land		charged:	\$	
		to cover the above fees i			610 to cover the above f	bas	
		nt No. <u>13-4500 (Order No</u> orized to charge any addi					
Deposit Ac	count No. <u>13-4500 (O</u>	rder No. 4439-4044)					
d . Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and							
granted to restore the application to pending status.							
SEND ALL CORRES	SFUNDENCE IU:				Muchal) L	Wills	
Enter Address Here			Signature		<del>y</del>	<u> </u>	
Morgan & Finnegan, L.L.P.			** .* *	I Camara-6-11	/ Michael A 337:11:-		
3 World Financial Center New York, New York 10281-2101			Kenneth I Name	Kenneth H. Sonnenfeld / Michael A. Willis Name			
Tel: (212) 415-8700							
Fax: (212) 415-8701 Registration No							
REGISTRATION NUMBER							

Form PTO-1390 (REV 7-2005)

### 10/583058

### IAP20 Rec'd PCT/PTO 14 JUN 2006

#### IN THE UNITED STATES

	RECEIVING OFFICE (RO/US)
$\boxtimes$	DESIGNATED OFFICE (DO/US
$\boxtimes$	ELECTED OFFICE (EO/US)

INTERNATIONAL APPLICATION PCT/JP2004/018646	INTERNATIONAL FILING DATE 14 December 2004	EARLIEST PRIORITY DATE CLAIMED 15 December 2003			
TITLE OF INVENTION					
Akt ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE					
APPLICANT(S) FOR DO/EO/US					
Masayuki NOGUCHI, Futoshi OKADA, and Shin HIROMURA					

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ATTN: DO/EO/US

## VERIFIED CERTIFICATION OF EXPRESS MAILING DATE (INTERNATIONAL APPLICATION (37 CFR 1.10(c))

I declare that on June 14, 2006, I deposited with the United States Postal Service in an envelope "Express Mail, Post Office to Addressee", bearing Label Number EV 826870244 US, addressed to the Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Attention: DO/EO/US and having an express mail certification which I executed, the following papers:

- 1. Transmittal Letter to the United States Designated/Elected Office;
- 2 English Translation of the International Application: (Specification: 37 pgs., Claims: 3 pgs.; Abstract: 1 pg.; and 5 Sheets of Formal Drawings (Figs.1-13));
- 3. Sequence Listing Statement;
- 4. Paper Copy of the Sequence Listing (4 pgs.) with a computer-readable form of the sequence listing;
- Copies of: PCT Request document; Forms: PCT/ISA/202; PCT/ISA/206; PCT/ISA/210; PCT/ISA/220; PCT/ISA/237; PCT/IB/301; PCT/IB/304, PCT/IB/307; PCT/IB/308; PCT/IB311 and PCT/IB/345 published PCT application.
- 6. Information Disclosure Statement; Forms r 10-1449A and PTO-1449B with copies of 13 cited references; and
- 7 Return receipt postcard.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

	Michael A. Willis
	(Typed or printed name of person making this verified statement)
June 14, 2006	Welly
Date	(Signature of person making this verified statement)

(Verified Certification of Express Mailing Date (International Application) [13-12])

## 10/583058

# LAPZUREC' d PCT/PTO 14 JUN 2006

Attorney's Docket No. 4439-4044

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Inventor:** 

Masayuki NOGUCHI, Futoshi OKADA, and Shin HIROMURA

Filed:

Herewith

Serial Number:

TBA

For:

Akt ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE

Statement Under 37 C.F.R. §1.821(f) or §1.825(b)

Mail Stop PCT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

I hereby certify that:

[X] The paper Sequence Listing submitted herewith and computer readable Sequence Listing attached hereto are identical (37 C.F.R. §1.821(f)).

[ ] The substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are identical. No new matter is included (37 C.F.R. §1.825(b)).

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Date: 14 June 2006

By:

Kenneth H. Sonnenfeld / Michael A. Willis

Registrations Nos. 33,285/53,913

Correspondence Address: MORGAN & FINNEGAN, L.L.P. Three World Financial Center New York, NY 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile